Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Sports Medicine CoHKSE:01609 -0.21%20 Return-on-Tangible-Equity is 32.55% as of Dec. 2025, which is 68% above its 10-year median of 19.39. GuruFocus rates HKSE:01609 with a GF Score™ of 20/100. The stock has 1 warning sign investors should review. Among 757 Medical Devices & Instruments companies, Star Sports Medicine Co ranks better than 52.44% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Star Sports Medicine Co's annualized net income for the quarter that ended in Dec. 2025 was HK$208.1 Mil. Star Sports Medicine Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was HK$639.5 Mil. Therefore, Star Sports Medicine Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 32.55%.
The historical rank and industry rank for Star Sports Medicine Co's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:01609'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 5.61 Med: 19.39 Max: 25.92
Current: 5.61
During the past 4 years, Star Sports Medicine Co's highest Return-on-Tangible-Equity was 25.92%. The lowest was 5.61%. And the median was 19.39%.
HKSE:01609's Return-on-Tangible-Equity is ranked better than 52.44% of 757
companies
in the Medical Devices & Instruments industry
Industry Median: 4.41
vs HKSE:01609: 5.61
Star Sports Medicine Co (HKSE:01609) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Star Sports Medicine Co Return-on-Tangible-Equity Related Terms
Star Sports Medicine Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Star Sports Medicine Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Sports Medicine Co Return-on-Tangible-Equity Chart
HKSE:01609 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Star Sports Medicine Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Sports Medicine Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Star Sports Medicine Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Star Sports Medicine Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 32.55% mean?
Star Sports Medicine Co (HKSE:01609) has a Return-on-Tangible-Equity of 32.55% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Star Sports Medicine Co and its competitors. This is 68% above median its historical median of 19.39. Over the past decade, Star Sports Medicine Co's Return-on-Tangible-Equity has ranged from 5.61 to 25.92. According to the industry distribution chart, Star Sports Medicine Co ranks #360 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 47.6%.
Is Star Sports Medicine Co's Return-on-Tangible-Equity too high?
Star Sports Medicine Co's current Return-on-Tangible-Equity of 32.55% is 68% above median its 10-year median of 19.39. Over the past 10 years, this metric has ranged from a low of 5.61 to a high of 25.92. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.41. Star Sports Medicine Co's value of 32.55% is 638.1% above this industry median. Based on the distribution chart, Star Sports Medicine Co ranks #360 out of 757 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Star Sports Medicine Co has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Star Sports Medicine Co's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Star Sports Medicine Co ranks #360 out of 757 companies for Return-on-Tangible-Equity. This puts Star Sports Medicine Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.41. Star Sports Medicine Co's value of 32.55% is 638.1% above this benchmark. Historically, Star Sports Medicine Co's own Return-on-Tangible-Equity has ranged from 5.61 to 25.92 over the past decade. While the company's 10-year median is 19.39 vs. the industry median of 4.41, Star Sports Medicine Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.41, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Sports Medicine Co's current Return-on-Tangible-Equity of 32.55% is 638.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Star Sports Medicine Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Sports Medicine Co's current Return-on-Tangible-Equity is 32.55%, which is 68% above median its own 10-year median of 19.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Sports Medicine Co stock overvalued right now?
Star Sports Medicine Co (HKSE:01609) has a current Return-on-Tangible-Equity of 32.55%. The current Return-on-Tangible-Equity is 32.55%, which is 68% above median its 10-year median of 19.39 and 638.1% above the Medical Devices & Instruments industry median of 4.41. Star Sports Medicine Co's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Star Sports Medicine Co (HKSE:01609), the current Return-on-Tangible-Equity is 32.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Star Sports Medicine Co Ltd is a China-based medical device company specializing in clinical sports medicine solutions. It is principally engaged in the research and development and sales of medical devices and equipment in the field of sports medicine. The product line covers medical implants, surgical equipment and associated medical consumables. The company has only one reportable operating segment, which is the sale of sports medicine products. It derives revenue from the sales of (i) medical implants and (ii) surgical equipment and associated medical consumables, with the majority of revenue generated from the sales of Medical implants. Geographically, the maximum revenue is derived from the Chinese mainland.
20GF Score
Get the complete analysis for HKSE:01609
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01609 has been successfully added to your 
